Insmed

Insmed is a US biopharmaceutical company with commercial-stage and late-pipeline products spanning respiratory, inflammatory and rare neurological diseases.

Its Cambridge facility at Babraham Research Campus, established through the 2023 acquisition of Adrestia, leads drug discovery using the company's synthetic rescue platform, targeting modifier genes to restore function in serious genetic diseases.

Cambridge programmes focus on neurodegenerative and rare conditions including ataxia telangiectasia and ALS, alongside gene therapy assets for Duchenne muscular dystrophy and Stargardt disease.